Q2 2025 Management View CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, ...

ResMed Inc (RMD) reports a 10% revenue increase and significant margin expansion, driven by robust device sales and strategic ...

ResMed Inc.’s RMD adjusted earnings per share (EPS) in the second quarter of fiscal 2025 were $2.43, up 29.2% year over year.

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

ResMed (ASX: RMD) posted a solid December quarter, with most figures slightly exceeding market expectations, driven by strong ...

In fiscal 2020, both ResMed and Philips reported selling over 10 million total cloud-connectable ... the launch of its new flagship product, AirSense 11, improving OSA diagnosis rates, and Philips ...

ResMed reported a revenue increase of 10% year-over-year ... attributed to manufacturing and cost improvements. The AirSense 11 has become the majority of ResMed's global product mix, which ...

ResMed's 10.2% revenue jump in Q2 was driven by strong demand for sleep health products, with a particular focus on expansion in digital health platforms. The 29.3% year-over-year bump up in ...

UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

(Image Credits: Pixabay) ResMed on Tuesday announced that it has launched AirSense 11 in India. According to the company’s statement, it is the next-generation Continuous Positive Airway ...

Device sales, including AirSense 10 and AirSense 11 ... and potentially redefining market standards for CPAP masks. ResMed also collaborated with Apple Vision Pro to introduce the Kontor Head ...